Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2014. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction and does not contain consolidated financial statements or performance metrics.
Material Changes
The filing details a transaction by Mr. W Louv, a Person Discharging Managerial Responsibilities, on November 17, 2014:
- Exercise of options over 11,870 GSK American Depositary Shares (ADSs) granted on December 2, 2004, at a price of $43.73 per ADS.
- Immediate sale of the 11,870 GSK ADSs at a price of $45.93 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of an insider trade.
Investor Verification Points
- Verify the total number of ADSs held by Mr. W Louv following this transaction.
- Confirm the pricing of the ADSs on November 17, 2014, to validate the reported sale price of $45.93.
- Review the GlaxoSmithKline Share Option Plan terms regarding the 2004 grant exercise.